Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial